CEO behind HIV drug Truvada grilled on $3B in profits
02:23
Daniel O’Day, the chairman and CEO of Gliead Sciences Inc., is asked to explain U.S. pricing of HIV prevention drug Truvada for PrEP along with his company’s profits and his $30M signing bonus.May 17, 2019
UP NEXT
London celebrates 50 years of Pride
01:40
One in five adult members of Gen Z self-identifies as LGBTQ
02:13
Police: Florida man killed teen because he feared being 'outed'
01:43
Florida teachers express concern over so-called 'Don't Say Gay' law
01:48
New York City running low on monkeypox vaccine
01:32
Thousands march in pride parades across the country